Bexmarilimab is a humanized monoclonal antibody against Clever-1, a macrophage scavenger receptor known to induce intratumoural immunosuppression. Bexmarilimab has been investigated for the treatment of solid tumors.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.